Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02467270
Registration number
NCT02467270
Ethics application status
Date submitted
2/06/2015
Date registered
10/06/2015
Date last updated
6/02/2024
Titles & IDs
Public title
Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses
Query!
Scientific title
A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses
Query!
Secondary ID [1]
0
0
2014-001617-12
Query!
Secondary ID [2]
0
0
AP24534-14-203
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
OPTIC
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Myeloid Leukemia, Chronic, Chronic Phase
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Leukaemia - Acute leukaemia
Query!
Cancer
0
0
0
0
Query!
Leukaemia - Chronic leukaemia
Query!
Cancer
0
0
0
0
Query!
Children's - Leukaemia & Lymphoma
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Ponatinib
Experimental: Cohort A: Ponatinib 45 mg - Ponatinib 45 mg orally once daily in each 28-day cycle until achievement of =1% BCR-ABL1IS up to data cut-off: 31 May 2020. Once =1% BCR-ABL1IS was achieved, participants received reduced dose of ponatinib 15 mg orally once daily.
Experimental: Cohort B: Ponatinib 30 mg - Ponatinib 30 mg orally once daily in each 28 day Cycle until achievement of =1% BCR-ABL1IS. Once =1% BCR-ABL1IS up to data cut-off: 31 May 2020. Once =1% BCR-ABL1IS was achieved, participants received reduced dose of ponatinib 15 mg orally once daily.
Experimental: Cohort C: Ponatinib 15 mg - Participants received ponatinib 15 mg orally once daily up to data cut-off: 31 May 2020 in each 28 day Cycle.
Treatment: Drugs: Ponatinib
Tablet, taken orally once daily.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants With Molecular Response (MR2: <=1% Breakpoint Cluster Region-Abelson Transcript Level) as Measured by the International Scale (BCR-ABL1IS) at Month 12
Query!
Assessment method [1]
0
0
MR2 is defined as a ratio of reverse transcribed transcript of BCR-ABL to ABL <=1% Breakpoint Cluster Region-Abelson Transcript Level as Measured by the International Scale (BCR-ABL1IS), equivalent to a 2-log reduction in transcript.
Query!
Timepoint [1]
0
0
12 months after the first dose of study treatment
Query!
Secondary outcome [1]
0
0
Percentage of Participants With Major Molecular Response (MMR/MR3)
Query!
Assessment method [1]
0
0
MMR/MR3 is defined as a ratio of reverse transcribed transcript of BCR-ABL to ABL =0.1% on the international scale (equivalent to a 3-log reduction in transcript).
Query!
Timepoint [1]
0
0
12 months after the first dose of study treatment
Query!
Secondary outcome [2]
0
0
Percentage of Participants With Major Cytogenetic Response (MCyR)
Query!
Assessment method [2]
0
0
MCyR is defined as percentage of participants with complete cytogenetic response (CCyR) or partial cytogenetic response (PCyR). Cytogenetic response is the percentage of Philadelphia chromosome positive (Ph+) metaphases in bone marrow (BM). Response is further defined as MCyR: CCyR or PCyR, where CCyR: 0% Ph + metaphases; PCyR: >0 to 35% Ph + metaphases.
Query!
Timepoint [2]
0
0
12 months after the first dose of study treatment
Query!
Secondary outcome [3]
0
0
Duration of Major Molecular Response (MMR/MR3)
Query!
Assessment method [3]
0
0
Duration of MMR/MR3 is defined as the interval between the first assessment at which the criteria for <=0.1% MMR are met until the earliest date at which loss of <=0.1% MMR occurs, or the criteria for progression are met. Progression to accelerated phase (AP) is defined as: >= 15% and <30% blasts in peripheral blood or bone marrow or >=20% basophils in peripheral blood or bone marrow or >=30% blasts + promyelocytes in peripheral blood or bone marrow (but <30% blasts) or <100*109 platelets per liter (/L) in peripheral blood unrelated to therapy or cytogenetic, genetic evidence of clonal evolution, and no extramedullary disease. Progression to blast Phase (BP) is defined as: >=30% blasts in peripheral blood or bone marrow or extramedullary disease other than hepatosplenomegaly.
Query!
Timepoint [3]
0
0
Baseline up to approximately 8 years
Query!
Secondary outcome [4]
0
0
Percentage of Participants With Adjusted Incidence Rates for Treatment Emergent Arterial Occlusive Events (AOEs), Venous Thrombotic Events (VTEs), Adverse Events (AEs), and Serious AEs (SAEs)
Query!
Assessment method [4]
0
0
Percentage of participants with adjusted incidence rates who developed AOEs and VTEs were categorized according to arterial occlusive events and venous thrombotic events. AE is any untoward medical occurrence in participant administered medicinal investigational drug. Untoward medical occurrence does not necessarily have to have causal relationship with treatment. SAE is any untoward medical occurrence that results in death; is life-threatening; requires inpatient hospitalization or prolongation of present hospitalization; results in persistent or significant disability/incapacity; is congenital anomaly/birth defect/is medically important event that may not be immediately life-threatening/result in death or hospitalization, but may jeopardize participant/may require intervention to prevent one of other outcomes listed in definition above, or involves suspected transmission via a medicinal product of an infectious agent.
Query!
Timepoint [4]
0
0
From first dose up to 30 days after last dose of the study drug up to data cut-off date: 31 May 2020 (Up to approximately 5 years)
Query!
Secondary outcome [5]
0
0
Percentage of Participants With Complete Cytogenetic Response (CCyR)
Query!
Assessment method [5]
0
0
Cytogenetic response is defined as the percentage of Ph+ metaphases in bone marrow (peripheral blood may not be used), with a review of a minimum of 20 metaphases. CCyR is defined as 0% Ph+ metaphases.
Query!
Timepoint [5]
0
0
Month 12
Query!
Secondary outcome [6]
0
0
Percentage of Participants With Molecular Response 4 (MR4) and Molecular Response (MR4.5)
Query!
Assessment method [6]
0
0
MR4 is defined as <=0.01% BCR-ABL1IS. MR 4.5 is defined as <=0.0032% BCR-ALB1IS.
Query!
Timepoint [6]
0
0
Up to approximately 8 years
Query!
Secondary outcome [7]
0
0
Percentage of Participants With Molecular Response 1 (MR1)
Query!
Assessment method [7]
0
0
MR1 is defined as percentage of participants achieving a ratio of <=10% Breakpoint Cluster Region-abelson (BCR-ABL1) transcripts on the international scale. MR1 is molecular response with 1-log reduction in transcript.
Query!
Timepoint [7]
0
0
3 months after the first dose of study treatment
Query!
Secondary outcome [8]
0
0
Percentage of Participants With Complete Hematologic Response (CHR)
Query!
Assessment method [8]
0
0
CHR is defined as achieving all of the following measurements: white blood cells (WBC) <= institutional upper limit of normal (ULN), platelets <450,000 per cubic millimeter (/mm^3), no blasts or promyelocytes in peripheral blood, <5% myelocytes plus metamyelocytes in peripheral blood, basophils in peripheral blood <5%, and no extramedullary involvement (including no hepatomegaly or splenomegaly).
Query!
Timepoint [8]
0
0
3 months after the first dose of study treatment
Query!
Secondary outcome [9]
0
0
Percentage of Participants With Treatment Emergent AEs Leading to Treatment Discontinuation, Dose Reduction and Dose Interruption
Query!
Assessment method [9]
0
0
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug.
Query!
Timepoint [9]
0
0
Up to data cut-off: 31 May 2020 (Approximately 5 years)
Query!
Secondary outcome [10]
0
0
Kaplan-Meier Estimate of Duration of Response (DOR) of <=1% BCR-ABL1 IS (MR2) at Months 12 and 24
Query!
Assessment method [10]
0
0
DOR (=1% BCR-ABL1IS) is defined as interval between first assessment at which criteria for =1% BCR-ABL1IS are met until earliest date at which loss of =1% BCR-ABL1IS occurs, or criteria for progression accelerated phase (AP) or blast Phase (BP) of chronic myeloid leukemia (CML) are met. Loss of =1% BCR-ABL1IS is an increase to >1% of BCR-ABL1IS. Progression to AP: =15% and <30% blasts in peripheral blood or bone marrow or =20% basophils in peripheral blood or bone marrow or =30% blasts + promyelocytes in peripheral blood or bone marrow (but <30% blasts) or <100*109 platelets per liter in peripheral blood unrelated to therapy or cytogenetic, genetic evidence of clonal evolution, and no extramedullary disease. Progression to BP: =30% blasts in peripheral blood or bone marrow or extramedullary disease other than hepatosplenomegaly. Kaplan-Meier method was used for analysis of percentage of participants who achieved DOR of 12 and 24 months.
Query!
Timepoint [10]
0
0
12 and 24 months after the first dose of study treatment
Query!
Secondary outcome [11]
0
0
Kaplan-Meier Estimate of Duration of Response (DOR) of Major Molecular Response (MMR/MR3)
Query!
Assessment method [11]
0
0
Duration of MMR/MR3 is defined as interval between first assessment at which criteria for MMR are met until earliest date at which loss of MMR occurs, or criteria for progression (progression to AP or BP of CML) are met. Participants remaining in MMR will be censored at last date at which criteria for MMR are met. Loss of MMR is an increase to >0.1% of BCR-ABL1IS. Progression to AP: >= 15% and <30% blasts in peripheral blood or bone marrow or >=20% basophils in peripheral blood or bone marrow or >=30% blasts+promyelocytes in peripheral blood or bone marrow (but <30% blasts) or <100*109 platelets/L in peripheral blood unrelated to therapy or cytogenetic, genetic evidence of clonal evolution, and no extramedullary disease. Progression to BP: >=30% blasts in peripheral blood or bone marrow or extramedullary disease other than hepatosplenomegaly. Kaplan-Meier method was used for analysis of percentage of participants who achieved DOR of 12 and 24 months.
Query!
Timepoint [11]
0
0
12 and 24 months after the first dose of study treatment
Query!
Secondary outcome [12]
0
0
Duration of Response in Responders
Query!
Assessment method [12]
0
0
Duration of response in "responders" is defined as any participants who achieved =1% BCR-ABL1IS at any time during the study. Responders are defined as those participants who meet all of the following: are randomized and treated, respond at 12 months after the initiation of study treatment, and undergo baseline polymerase chain reaction (PCR) assessment.
Query!
Timepoint [12]
0
0
Baseline up to data cut-off: 31 May 2020 (Approximately 5 years)
Query!
Secondary outcome [13]
0
0
Time to Response
Query!
Assessment method [13]
0
0
Time to response was defined as the time interval from the date of the first dose of the study drug until the initial observation of CR or PR for participants with confirmed CR/PR. CR for target lesion: disappearance of all extranodal lesions and all pathological lymph nodes must have decreased to <10 mm in short axis. CR for non-target lesion: Disappearance of all extranodal non-target lesions, all lymph nodes must be non-pathological in size (<10mm short axis) and norrmalization of tumor marker level. PR: at least a 30% decrease in the SLD of target lesions, taking as reference the Baseline sum diameters.
Query!
Timepoint [13]
0
0
Baseline up to data cut-off: 31 May 2020 (Approximately 5 years)
Query!
Secondary outcome [14]
0
0
Percentage of Participants With Progression to Accelerated Phase (AP)-Chronic Myeloid Leukemia (CML) or Blast Phase (BP)-CML
Query!
Assessment method [14]
0
0
Progression to AP is defined as: >=15% and <30% blasts in peripheral blood or bone marrow or >=20% basophils in peripheral blood or bone marrow or >=30% blasts + promyelocytes in peripheral blood or bone marrow (but <30% blasts) or <100*109 platelets/L in peripheral blood unrelated to therapy or cytogenetic, genetic evidence of clonal evolution, and no extramedullary disease. Progression to BP is defined as: >=30% blasts in peripheral blood or bone marrow or extramedullary disease other than hepatosplenomegaly.
Query!
Timepoint [14]
0
0
From first dose date of study treatment up to data cut-off: 31 May 2020 (Approximately 5 years)
Query!
Secondary outcome [15]
0
0
Progression-free Survival (PFS)
Query!
Assessment method [15]
0
0
PFS is defined as the interval between the first dose date of study treatment and the first date at which the criteria for progression are met (progression to the AP or BP of CML), or death due to any cause, censored at the last response assessment. Progression to AP is defined as: >=15% and <30% blasts in peripheral blood or bone marrow or >=20% basophils in peripheral blood or bone marrow or >=30% blasts + promyelocytes in peripheral blood or bone marrow (but <30% blasts) or <100*109 platelets/L in peripheral blood unrelated to therapy or cytogenetic, genetic evidence of clonal evolution, and no extramedullary disease. Progression to BP is defined as: >=30% blasts in peripheral blood or bone marrow or extramedullary disease other than hepatosplenomegaly.
Query!
Timepoint [15]
0
0
Up to data cut-off: 31 May 2020 (Up to approximately 5 years)
Query!
Secondary outcome [16]
0
0
Overall Survival (OS)
Query!
Assessment method [16]
0
0
OS is defined as the interval between the first does of study treatment and death due to any cause, censored at the last contact date when the participant was alive.
Query!
Timepoint [16]
0
0
Up to data cut-off: 31 May 2020 (Up to approximately 5 years)
Query!
Eligibility
Key inclusion criteria
1. Have chronic phase-chronic myelogenous leukemia/chronic myeloid leukemia (CP-CML) and
have received at least two prior tyrosine kinase inhibitor (TKI) therapies and have
demonstrated resistance to treatment OR have documented history of presence of T315I
mutation after receiving any number of prior TKI.
o] The diagnosis of chronic myeloid leukemia (CML) will be made using standard
hematopathologic and cytogenetic criteria; CP-CML will be defined by all of the
following: i <15% blasts in bone marrow ii <30% blasts plus promyelocytes in bone
marrow iii <20% basophils in peripheral blood. iv >= 100*10^9/liter (L) platelets
(>=100,000/mm^3). v No evidence of extramedullary disease except hepatosplenomegaly vi
No prior diagnosis of AP-CML, and BP-CML o] Cytogenetic assessment at screening must
demonstrate the BCR-ABL1 fusion by presence of the t(9;22) Philadelphia chromosome.
i Variant translocations are only allowed provided they meet inclusion criterion 1d.
o] Resistance to prior TKI therapy is defined as follows (participants must meet at
least 1 criterion): i Three months after the initiation of prior TKI therapy: No
cytogenetic response (>95% Ph+) or failure to achieve CHR or new mutation ii Six
months after the initiation of prior TKI therapy: BCR-ABL1IS >10% and/or Ph+ >65% or
new mutation iii Twelve months after the initiation of prior TKI therapy: BCR ABL1IS
>10% and/or Ph+ >35% or new mutation iv At any time after the initiation of prior TKI
therapy, the development of a new BCR-ABL1 kinase domain mutation(s) v At any time
after the initiation of prior TKI therapy, the development of new clonal evolution vi
At any time after the initiation of prior TKI therapy, the loss of CHR, or CCyR, or
the confirmed loss of MMR in 2 consecutive tests, one of which has a BCR-ABL1IS
transcript level of >=1% or new mutation o] >1% of BCR-ABL1IS as shown by real-time
polymerase chain reaction
2. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.
3. Have adequate renal function as defined by the following criterion:
o] Serum creatinine <=1.5*ULN for institution o] Estimated creatinine clearance >=30
milliliter per minute (mL/min) (Cockcroft-Gault formula)
4. Have adequate hepatic function as defined by the following criteria:
o] Total serum bilirubin <=1.5*ULN, unless due to Gilbert's syndrome o] Alanine
transaminase (ALT) <=2.5*ULN, or <=5*ULN if leukemic infiltration of the liver is
present o] Aspartate transaminase (AST) <=2.5*ULN, or <=5*ULN if leukemic infiltration
of the liver is present
5. Have normal pancreatic status as defined by the following criterion:
o] Serum lipase and amylase <=1.5*ULN
6. Have normal QT interval corrected (Frederica) (QTcF) interval on screening
electrocardiogram (ECG) evaluation, defined as QTcF of <=450 milliseconds (ms) in
males or <=470 ms in females.
7. Have a negative pregnancy test documented prior to enrollment (for females of
childbearing potential).
8. Agree to use a highly effective form of contraception with sexual partners from
randomization through at least 4 months after the end of treatment (for female and
male participants who are fertile).
9. Provide written informed consent.
10. Be willing and able to comply with scheduled visits and study procedures.
11. Have recovered from toxicities related to prior anticancer therapy to National Cancer
Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v 4.0 grade
<=1.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Have used any approved TKIs or investigational agents within 2 weeks or 6 half-lives
of the agent, whichever is longer, prior to receiving study drug.
2. Received interferon, cytarabine, or immunotherapy within 14 days, or any other
cytotoxic chemotherapy, radiotherapy, or investigational therapy within 28 days prior
to receiving the first dose of ponatinib, or have not recovered (>grade 1 by NCI
CTCAE, version 4.0) from AEs (except alopecia), due to agents previously administered.
3. Have undergone autologous or allogeneic stem cell transplant <60 days prior to
receiving the first dose of ponatinib; have any evidence of ongoing graft-versus-host
disease (GVHD) or GVHD requiring immunosuppressive therapy.
4. Are being considered for hematopoietic stem cell transplant (HSCT) within 6-12 months
of enrollment (note: ponatinib is not to be used as a bridge to HSCT in this trial).
5. Are taking medications with a known risk of Torsades de Pointes.
6. Have previously been treated with ponatinib.
7. Have active CNS disease as evidenced by cytology or pathology; in the absence of
clinical CNS disease, lumbar puncture is not required. History itself of CNS
involvement is not exclusionary if CNS has been cleared with a documented negative
lumbar puncture.
8. Have clinically significant, uncontrolled, or active cardiovascular disease,
specifically including, but not restricted to:
o] Any history of myocardial infarction (MI), unstable angina, cerebrovascular
accident, or Transient Ischemic Attack (TIA) o] Any history of peripheral vascular
infarction, including visceral infarction o] Any revascularization procedure,
including the placement of a stent o] Congestive heart failure (CHF) (New York Heart
Association [NYHA] class III or IV) within 6 months prior to enrollment, or left
ventricular ejection fraction (LVEF) less than lower limit of normal, per local
institutional standards, within 6 months prior to enrollment o] History of clinically
significant (as determined by the treating physician) atrial arrhythmia or any history
of ventricular arrhythmia o] Venous thromboembolism, including deep venous thrombosis
or pulmonary embolism, within 6 months prior to enrollment
9. Have uncontrolled hypertension (that is, >150 and >90 for systolic blood pressure
(SBP) and diastolic blood pressure (DBP) respectively). Participants with hypertension
should be under treatment at study entry to ensure blood pressure control. Those
requiring 3 or more antihypertensive medications should be discussed with the medical
monitor.
10. Have poorly controlled diabetes defined as HbA1c values of >7.5%. Participants with
preexisting, well-controlled diabetes are not excluded.
11. Have a significant bleeding disorder unrelated to CML.
12. Have a history of alcohol abuse.
13. Have a history of either acute pancreatitis within 1 year of study enrollment or of
chronic pancreatitis.
14. Have malabsorption syndrome or other gastrointestinal illness that could affect oral
absorption of study drug.
15. Have a history of another malignancy, other than cervical cancer in situ or basal cell
or squamous cell carcinoma of the skin; the exception is if participants have been
disease-free for at least 5 years, and are deemed by the investigator to be at low
risk for recurrence of that malignancy.
16. Are pregnant or lactating.
17. Have undergone major surgery (with the exception of minor surgical procedures, such as
catheter placement or BM biopsy) within 14 days prior to first dose of ponatinib.
18. Have an active infection which requires intravenous antibiotics.
19. Have a known history of human immunodeficiency virus infection; testing is not
required in the absence of prior documentation or known history.
20. Have any condition or illness that, in the opinion of the investigator, would
compromise participant safety or interfere with the evaluation of the drug.
21. Have hypersensitivity to the ponatinib active substance or to any of its inactive
ingredients.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
30/06/2015
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
1/06/2024
Query!
Actual
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
283
Query!
Recruitment in Australia
Recruitment state(s)
NSW,SA
Query!
Recruitment hospital [1]
0
0
Royal North Shore Hospital - Saint Leonards
Query!
Recruitment hospital [2]
0
0
Royal Adelaide Hospital - Adelaide
Query!
Recruitment postcode(s) [1]
0
0
2065 - Saint Leonards
Query!
Recruitment postcode(s) [2]
0
0
5000 - Adelaide
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Georgia
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Indiana
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Maryland
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Michigan
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Minnesota
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Nebraska
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
New Jersey
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
New York
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
North Carolina
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Ohio
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Oregon
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Pennsylvania
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Texas
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Utah
Query!
Country [15]
0
0
Argentina
Query!
State/province [15]
0
0
Buenos Aires
Query!
Country [16]
0
0
Canada
Query!
State/province [16]
0
0
Ontario
Query!
Country [17]
0
0
Canada
Query!
State/province [17]
0
0
Quebec
Query!
Country [18]
0
0
Canada
Query!
State/province [18]
0
0
Saskatchewan
Query!
Country [19]
0
0
Chile
Query!
State/province [19]
0
0
Santiago
Query!
Country [20]
0
0
Chile
Query!
State/province [20]
0
0
Valparaiso
Query!
Country [21]
0
0
Czechia
Query!
State/province [21]
0
0
Praha
Query!
Country [22]
0
0
Czechia
Query!
State/province [22]
0
0
Olomouc
Query!
Country [23]
0
0
Denmark
Query!
State/province [23]
0
0
\Aarhus
Query!
Country [24]
0
0
France
Query!
State/province [24]
0
0
Aquitaine
Query!
Country [25]
0
0
France
Query!
State/province [25]
0
0
Lorraine
Query!
Country [26]
0
0
France
Query!
State/province [26]
0
0
Midi-pyrenees
Query!
Country [27]
0
0
France
Query!
State/province [27]
0
0
NORD Pas-de-calais
Query!
Country [28]
0
0
France
Query!
State/province [28]
0
0
PAYS DE LA Loire
Query!
Country [29]
0
0
France
Query!
State/province [29]
0
0
Poitou-charentes
Query!
Country [30]
0
0
France
Query!
State/province [30]
0
0
Provence Alpes COTE D'azur
Query!
Country [31]
0
0
Germany
Query!
State/province [31]
0
0
Baden-wuerttemberg
Query!
Country [32]
0
0
Germany
Query!
State/province [32]
0
0
Mecklenburg-vorpommern
Query!
Country [33]
0
0
Germany
Query!
State/province [33]
0
0
Nordrhein-westfalen
Query!
Country [34]
0
0
Germany
Query!
State/province [34]
0
0
Thuringen
Query!
Country [35]
0
0
Germany
Query!
State/province [35]
0
0
Berlin
Query!
Country [36]
0
0
Germany
Query!
State/province [36]
0
0
Hamburg
Query!
Country [37]
0
0
Hong Kong
Query!
State/province [37]
0
0
Hong Kong
Query!
Country [38]
0
0
Italy
Query!
State/province [38]
0
0
Monza E Brianza
Query!
Country [39]
0
0
Italy
Query!
State/province [39]
0
0
Pesaro E Urbino
Query!
Country [40]
0
0
Italy
Query!
State/province [40]
0
0
Catania
Query!
Country [41]
0
0
Italy
Query!
State/province [41]
0
0
Genova
Query!
Country [42]
0
0
Italy
Query!
State/province [42]
0
0
Pescara
Query!
Country [43]
0
0
Italy
Query!
State/province [43]
0
0
Roma
Query!
Country [44]
0
0
Italy
Query!
State/province [44]
0
0
Verona
Query!
Country [45]
0
0
Korea, Republic of
Query!
State/province [45]
0
0
Seoul
Query!
Country [46]
0
0
Poland
Query!
State/province [46]
0
0
Dolnoslaskie
Query!
Country [47]
0
0
Poland
Query!
State/province [47]
0
0
Lodzkie
Query!
Country [48]
0
0
Poland
Query!
State/province [48]
0
0
Malopolskie
Query!
Country [49]
0
0
Poland
Query!
State/province [49]
0
0
Mazowieckie
Query!
Country [50]
0
0
Poland
Query!
State/province [50]
0
0
Pomorskie
Query!
Country [51]
0
0
Portugal
Query!
State/province [51]
0
0
Lisboa
Query!
Country [52]
0
0
Portugal
Query!
State/province [52]
0
0
Porto
Query!
Country [53]
0
0
Russian Federation
Query!
State/province [53]
0
0
Rostov
Query!
Country [54]
0
0
Russian Federation
Query!
State/province [54]
0
0
Chelyabinsk
Query!
Country [55]
0
0
Russian Federation
Query!
State/province [55]
0
0
Kemerovo
Query!
Country [56]
0
0
Russian Federation
Query!
State/province [56]
0
0
Moscow
Query!
Country [57]
0
0
Russian Federation
Query!
State/province [57]
0
0
Saint Petersburg
Query!
Country [58]
0
0
Russian Federation
Query!
State/province [58]
0
0
Samara
Query!
Country [59]
0
0
Russian Federation
Query!
State/province [59]
0
0
Saratov
Query!
Country [60]
0
0
Singapore
Query!
State/province [60]
0
0
Singapore
Query!
Country [61]
0
0
Spain
Query!
State/province [61]
0
0
Andalucia
Query!
Country [62]
0
0
Spain
Query!
State/province [62]
0
0
LAS Palmas
Query!
Country [63]
0
0
Spain
Query!
State/province [63]
0
0
Barcelona
Query!
Country [64]
0
0
Spain
Query!
State/province [64]
0
0
Madrid
Query!
Country [65]
0
0
Spain
Query!
State/province [65]
0
0
Valencia
Query!
Country [66]
0
0
Sweden
Query!
State/province [66]
0
0
Uppsala
Query!
Country [67]
0
0
Switzerland
Query!
State/province [67]
0
0
Zurich
Query!
Country [68]
0
0
Taiwan
Query!
State/province [68]
0
0
Taipei
Query!
Country [69]
0
0
United Kingdom
Query!
State/province [69]
0
0
England
Query!
Country [70]
0
0
United Kingdom
Query!
State/province [70]
0
0
Scotland
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Takeda
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to characterize the efficacy of ponatinib administered in 3
starting doses (45 mg, 30 mg, and 15 mg daily) in participants with CP-CML who are resistant
to prior tyrosine-kinase inhibitor (TKI) therapy or have T315I mutation, as measured by <=1 %
Breakpoint Cluster Region-Abelson Transcript Level using International Scale (BCR-ABL1IS) at
12 months.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02467270
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Study Director Clinical Science
Query!
Address
0
0
Takeda
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02467270
Download to PDF